)
)
Alumis Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Alumis Inc
Access all reports
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for autoimmune diseases. The company's research primarily targets allosteric inhibitors of tyrosine kinase 2 (TYK2), with potential applications in treating conditions like psoriasis, systemic lupus erythematosus, and neuroinflammatory disorders. Alumis employs a precision medicine approach to its drug development process, aiming to create targeted therapies for specific immune-related conditions. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
ALMS
Country
🇺🇸 United States